Stonepine Capital Management LLC Sells 351,215 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Stonepine Capital Management LLC decreased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 35.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 648,785 shares of the biotechnology company’s stock after selling 351,215 shares during the quarter. Ironwood Pharmaceuticals makes up about 2.3% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC’s holdings in Ironwood Pharmaceuticals were worth $2,874,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in IRWD. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ironwood Pharmaceuticals during the 4th quarter worth about $36,000. Journey Strategic Wealth LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $45,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $47,000. Xponance Inc. bought a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $50,000. Finally, Envestnet Asset Management Inc. acquired a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $50,000.

Analyst Upgrades and Downgrades

IRWD has been the topic of several recent analyst reports. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Jefferies Financial Group reissued a “hold” rating and issued a $0.70 target price (down from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Citizens Jmp lowered shares of Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, April 14th. Craig Hallum cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 16th. Finally, JMP Securities lowered their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday, January 30th. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.78.

Ironwood Pharmaceuticals Trading Down 4.1%

IRWD opened at $0.57 on Friday. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.53 and a 1-year high of $7.11. The stock’s fifty day simple moving average is $1.07 and its 200 day simple moving average is $2.54. The stock has a market cap of $92.24 million, a PE ratio of -19.00 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.09). The company had revenue of $41.14 million during the quarter, compared to analyst estimates of $67.02 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.